A Phase 3 interventional study of surfactant and surfactant+vitamin A in RDS, Infant, Newborn and Vitamin A, sponsored by Third Military Medical University. Status unknown at 1 site in China. Open to participants aged Up to 28 Days. Per ClinicalTrials.gov, last updated 2011-07-26.
Sponsored by Third Military Medical University · Phase 3, Interventional, and Treatment
To research the effect of vitamin A to newborn respiratory distress syndrome by intratracheal administration with surfactant.
Chronic lung disease (CLD) of prematurity is the major cause of long-term disability of extremely LBW (ELBW) premature infants, and it is the most cost consumptive disease in Neonatal Intensive Care Unit graduates. Vitamin A plays an important role in the development of premature lung. Nevertheless, premature infants are prone to vitamin A deficiency. Oral supplementation of vitamin A does not alter the incidence of CLD in ELBW infants. Intramuscular administration of vitamin A reduced the incidence of CLD. The treatment is considered painful and this way is not routinely practiced. Vitamin A is systemically bioavailable after intratracheal administration with surfactant in an animal model of newborn respiratory distress.
1,597 studies on the registry are indexed under Respiratory Distress Syndrome; 312 are open to participants now.
This study's planned enrollment of 100 is above the median of 60 across 961 interventional studies indexed under Respiratory Distress Syndrome.
Browse Respiratory Distress Syndrome studies →Third Military Medical University is the lead sponsor of 81 studies on the registry; 16 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
Drug: surfactant
Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
Drug: surfactant+vitamin A
Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
Intratracheal Vitamin A Administration with Surfactant for Newborn Respiratory Distress Syndrome
get the date of infants' reflects with Intratracheal Vitamin A Administration
Time frame: 1 year
Overall clinical outcomes at Newborn Infants With Respiratory Distress Syndrome
analysis the date and drow a conclusion
Time frame: 13 months
This study is status unknown, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome→
Third Military Medical University